Comments on “DNA-binding activities of compounds acting as enzyme inhibitors, ion channel blockers and receptor binders.”

Jaeschke, Hartmut

doi:10.1016/j.cbi.2021.109761

Chemico-Biological Interactions

2022

DOI: 10.1016/j.cbi.2021.109761

|View full text |Cite

Comments on “DNA-binding activities of compounds acting as enzyme inhibitors, ion channel blockers and receptor binders.”

Hartmut Jaeschke

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs

et al. 2022

View full text Add to dashboard Cite

Mutations of ion channels and G-protein-coupled receptors (GPCRs) are not uncommon and can lead to cardiovascular diseases. Given previously reported multiple factors associated with high mutation rates, we sorted the relative mutability of multiple human genes by (i) proximity to telomeres and/or (ii) high adenine and thymine (A+T) content. We extracted genomic information using the genome data viewer and examined the mutability of 118 ion channel and 143 GPCR genes based on their association with factors (i) and (ii). We then assessed these two factors with 31 genes encoding ion channels or GPCRs that are targeted by the United States Food and Drug Administration (FDA)-approved drugs. Out of the 118 ion channel genes studied, 80 met either factor (i) or (ii), resulting in a 68% match. In contrast, a 78% match was found for the 143 GPCR genes. We also found that the GPCR genes (n = 20) targeted by FDA-approved drugs have a relatively lower mutability than those genes encoding ion channels (n = 11), where targeted genes encoding GPCRs were shorter in length. The result of this study suggests that the use of matching rate analysis on factor-druggable genome is feasible to systematically compare the relative mutability of GPCRs and ion channels. The analysis on chromosomes by two factors identified a unique characteristic of GPCRs, which have a significant relationship between their nucleotide sizes and proximity to telomeres, unlike most genetic loci susceptible to human diseases.

show abstract

Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs

et al. 2022

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Comments on “DNA-binding activities of compounds acting as enzyme inhibitors, ion channel blockers and receptor binders.”

Cited by 1 publication

References 13 publications

Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs

Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs

Contact Info

Product

Resources

About